Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Disseminated Tumor Cell: early-phase trial registry

1 of 1 indexed Disseminated Tumor Cell trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Disseminated Tumor Cell: 1 US clinical trial tracked, 1 recruiting.

Disseminated Tumor Cell is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Southern California, running 1 of these trials.

Enrollment posture brief

Registry condition disseminated-tumor-cell

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Disseminated Tumor Cell (thi…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Disseminated Tumor Cell

Disseminated Tumor Cell lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Disseminated Tumor Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Disseminated Tumor Cell is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Disseminated Tumor Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sarilumab 150mg plus Capecitabine Combination
1 trials
Sarilumab 150mg or 200 mg plus Capecitabine Combination
1 trials
Capecitabine Drug
1 trials

US sites by state

Facility locations filed on Disseminated Tumor Cell trials. A trial with sites in several states counts in each.

Florida 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Disseminated Tumor Cell page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Disseminated Tumor Cell condition card totals 1 registered trials; most-linked intervention Sarilumab 150mg plus Capecitabine; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.